Biora Therapeutics, Inc.(BIOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIOR Biora Therapeutics, Inc.

Market Closed 05-17 16:00:00 EDT

0.7297

-0.0076

-1.03%

盘后0.7003

-0.0294-4.03%

19:53 EDT

High0.7500	Low0.7001	Vol220.45K
Open0.7400	D1 Closing0.7373	Amplitude6.77%
Mkt Cap26.18M	Tradable Cap11.88M	Total Shares35.88M
T/O160.12K	T/O Rate1.35%	Tradable Shares16.27M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BIOR","market":"US","secType":"STK","nameCN":"Biora Therapeutics, Inc.","latestPrice":0.7297,"timestamp":1715976000000,"preClose":0.7373,"halted":0,"volume":220453,"hourTrading":{"tag":"盘后","latestPrice":0.7003,"preClose":0.7297,"latestTime":"19:53 EDT","volume":985,"amount":703.1464,"timestamp":1715990002832},"delay":0,"floatShares":16274840,"shares":35883843,"eps":-7.868678,"marketStatus":"Market Closed","change":-0.0076,"latestTime":"05-17 16:00:00 EDT","open":0.74,"high":0.75,"low":0.7001,"amount":160120.63545149998,"amplitude":0.067679,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.868678,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1716192000000},"marketStatusCode":7,"adr":0,"listingDate":1592539200000,"exchange":"NASDAQ","adjPreClose":0.7373,"preHourTrading":{"tag":"盘前","latestPrice":0.75,"preClose":0.7373,"latestTime":"09:27 EDT","volume":2201,"amount":1617.6788745,"timestamp":1715952433575},"postHourTrading":{"tag":"盘后","latestPrice":0.7003,"preClose":0.7297,"latestTime":"19:53 EDT","volume":985,"amount":703.1464,"timestamp":1715990002832},"volumeRatio":1.0111669482117567},"requestUrl":"/m/hq/s/BIOR/","defaultTab":"news","newsList":[{"id":"2436041983","title":"BIOR: BT-600 Data in June","url":"https://stock-news.laohu8.com/highlight/detail?id=2436041983","media":"Zacks Small Cap Research","top":-1,"share":"https://ttm.financial/m/news/2436041983?lang=en_us&edition=fundamental","pubTime":"2024-05-16 21:56","pubTimestamp":1715867760,"startTime":"0","endTime":"0","summary":"Biora Therapeutics, Inc.  reported first quarter results encapsulating a period during which it has initiated its BT-600 Phase I study, added new collaborators to its BioJet program, completed several cohorts of its clinical study and improved its capital structure. Following the end of the quarter, Biora shared interim results from the BT-600 trial, raised additional capital and completed the multiple-ascending dose portion of the BT-600 trial. Other highlights include the issuance of a new patent and participation in Digestive Disease Week on May 19th. Based on the preclinical work that has been completed so far with collaborators, management is optimistic that they will see a partnership emerge this year.Biora reported first quarter 2024 results in a press release and Form 10-Q filing with the SEC on May 15th. A conference call was held to discuss results with investors following the release. For the quarter ending March 31, 2024 revenues of $542,000 were recognized. Net loss for 1Q","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DM1CdzJYNGliVr3YTLsejA--~B/aD02ODg7dz0xODI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/47ccdcb1f6c0a48830e5d997ad1a8a7e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DM1CdzJYNGliVr3YTLsejA--~B/aD02ODg7dz0xODI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/47ccdcb1f6c0a48830e5d997ad1a8a7e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bior-bt-600-data-june-135600136.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435640701","title":"Biora Therapeutics Inc (BIOR) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2435640701","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2435640701?lang=en_us&edition=fundamental","pubTime":"2024-05-16 15:08","pubTimestamp":1715843282,"startTime":"0","endTime":"0","summary":"Operating Cash Burn: $11.5 million for the quarter.Convertible Note Balance: Reduced to approximately $52 million by end of Q1 2024.Total Capital Raised: Over $31 million in the last four months.GuruFocus has detected 6 Warning Signs with BIOR.For the complete transcript of the earnings call, please refer to the full earnings call transcript.The Navigator platform demonstrated effective and targeted drug delivery, potentially leading to improved efficacy and reduced toxicity for ulcerative colitis patients.Biora Therapeutics Inc  has made significant advancements in their budget and systemic therapeutics platforms, with preclinical data demonstrating leading bioavailability of complex molecules.Q: What are the expectations for the upcoming top-line data for VP. 600?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biora-therapeutics-inc-bior-q1-070802148.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435442664","title":"Biora Therapeutics Q1 2024 GAAP EPS $(0.14) Beats $(0.45) Estimate, Sales $542.000K","url":"https://stock-news.laohu8.com/highlight/detail?id=2435442664","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2435442664?lang=en_us&edition=fundamental","pubTime":"2024-05-16 04:09","pubTimestamp":1715803789,"startTime":"0","endTime":"0","summary":"Biora Therapeutics (NASDAQ:BIOR) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.45) by 68.89 percent. This is a 77.78 percent increase over losses of $(0.63) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38856455/biora-therapeutics-q1-2024-gaap-eps-0-14-beats-0-45-estimate-sales-542-000k","is_publish_highlight":false,"gpt_icon":0},{"id":"2435130725","title":"Biora Therapeutics Inc    expected to post a loss of 45 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2435130725","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2435130725?lang=en_us&edition=fundamental","pubTime":"2024-05-14 04:36","pubTimestamp":1715632595,"startTime":"0","endTime":"0","summary":"* Biora Therapeutics Inc     is expected to show a fall in quarterly revenue when it reports  results on May 15 for the period ending March 31 2024   *    * LSEG's mean analyst estimate for Biora Ther","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431346270","title":"Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600","url":"https://stock-news.laohu8.com/highlight/detail?id=2431346270","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2431346270?lang=en_us&edition=fundamental","pubTime":"2024-04-30 20:00","pubTimestamp":1714478400,"startTime":"0","endTime":"0","summary":"Dosing of all patients in the trial has been successfully completed. Final results are expected to be available in late Q2 2024. SAN DIEGO, April 30, 2024  -- Biora Therapeutics, Inc. , the biotech company that is reimagining therapeutic delivery, today announced completion of dosing for the multiple-ascending dose cohorts for its clinical study of BT-600, a drug-device combination consisting of the orally administered NaviCap device that delivers a proprietary liquid formulation of tofacitinib to the colon. BT-600 is being developed for the potential treatment of patients with ulcerative colitis . The MAD portion of the trial evaluated daily doses of BT-600 for seven days at 5 mg and 10 mg tofacitinib or placebo, in healthy adult participants.About the NaviCap Targeted Oral Delivery Platform Biora's NaviCap targeted oral therapeutics platformutilizes a novel approach that could improve patient outcomes by enabling delivery of t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/t64IRG7Tl2D2ujODNpY_lA--~B/aD00Nzc7dz0xNDczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0877597311ae53204cffb0d12060da61","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/t64IRG7Tl2D2ujODNpY_lA--~B/aD00Nzc7dz0xNDczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0877597311ae53204cffb0d12060da61"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biora-therapeutics-announces-completion-multiple-120000666.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426091054","title":"BIOR Biotech has launched the world's first technology capable of affordably and continuously cultivating soil microorganisms.","url":"https://stock-news.laohu8.com/highlight/detail?id=2426091054","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2426091054?lang=en_us&edition=fundamental","pubTime":"2024-04-11 11:50","pubTimestamp":1712807400,"startTime":"0","endTime":"0","summary":"v=6v4IZhzB_u0&t=231sRelease ID: 89126716If there are any deficiencies, discrepancies, or concerns regarding the information presented in this press release, we kindly request that you promptly inform us by contacting [emailprotected]. Our dedicated team is committed to addressing any identified issues within 8 hours to guarantee the delivery of accurate and reliable content to our esteemed readers.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23053119","is_publish_highlight":false,"gpt_icon":0},{"id":"2426264199","title":"BRIEF-Biora Therapeutics Files Prospectus Relates To Offer & Resale By Selling Stockholder Of Up To 10.7 Mln Shares Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2426264199","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2426264199?lang=en_us&edition=fundamental","pubTime":"2024-04-09 04:29","pubTimestamp":1712608192,"startTime":"0","endTime":"0","summary":"April 8 (Reuters) - Biora Therapeutics Inc   :   * BIORA THERAPEUTICS- FILES PROSPECTUS RELATES TO OFFER & RESALE FROM TIME TO TIME BY SELLING STOCKHOLDER OF UP TO 10.7 MILLION SHARES OF COMMON STOCKSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426492198","title":"Biora Therapeutics files to sell 10.7M common shares for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2426492198","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426492198?lang=en_us&edition=fundamental","pubTime":"2024-04-09 04:26","pubTimestamp":1712608014,"startTime":"0","endTime":"0","summary":"Biora Therapeutics on Monday filed a prospectus related to the proposed resale of 10.7M common shares by the selling stockholders.This prospectus is not an offer to sell these securities.More on Biora Therapeutics  Biora Therapeutics, Inc.  Q4 2023 Earnings Call Transcript Biora Therapeutics wins new patent covering Biojet liquid jet delivery technology Biora Therapeutics reports positive results from its clinical trial of BT-600","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4088035-biora-therapeutics-files-to-sell-107m-common-shares-for-holders","is_publish_highlight":false,"gpt_icon":0},{"id":"2426944861","title":"Biora Therapeutics wins new patent covering Biojet liquid jet delivery technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2426944861","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426944861?lang=en_us&edition=fundamental","pubTime":"2024-04-08 23:10","pubTimestamp":1712589050,"startTime":"0","endTime":"0","summary":"Biora Therapeutics (NASDAQ:BIOR) Monday announced the issuance of a new patent related to the company’s BioJet platform for oral, systemic delivery of biotherapeutics. The issued claims cover key jet ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4087949-biora-therapeutics-wins-new-patent-covering-biojet-liquid-jet-delivery-technology","is_publish_highlight":false,"gpt_icon":0},{"id":"2425999991","title":"BRIEF-Biora Therapeutics Issued New Patent Covering Its BioJet Liquid Jet Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2425999991","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2425999991?lang=en_us&edition=fundamental","pubTime":"2024-04-08 20:48","pubTimestamp":1712580538,"startTime":"0","endTime":"0","summary":"April 8 (Reuters) - Biora Therapeutics Inc   :   * BIORA THERAPEUTICS ANNOUNCES NEW PATENT COVERING ITS BIOJET™ LIQUID JET DELIVERY TECHNOLOGYSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2424957394","title":"Biora Therapeutics reports positive results from its clinical trial of BT-600","url":"https://stock-news.laohu8.com/highlight/detail?id=2424957394","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424957394?lang=en_us&edition=fundamental","pubTime":"2024-04-04 20:55","pubTimestamp":1712235321,"startTime":"0","endTime":"0","summary":"Biora Therapeutics, Inc  shared additional positive interim results from clinical trial of BT-600, which is a drug-device combination consisting of the orally administered NaviCap device that delivers a proprietary liquid formulation of tofacitinib to the colon. According to the interim clinical data, all pharmacokinetic endpoints were met in all study participants.  BT-600 was well tolerated with no serious adverse events. All devices performed as intended, with all participants receiving BT-600 showing systemic drug absorption. Source: Press Release    More on Biora Therapeutics  Biora Therapeutics, Inc.  Q4 2023 Earnings Call Transcript Biora Therapeutics announces $6M registered direct offering and concurrent private placement Biora Therapeutics announces new capital investment Seeking Alpha’s Quant Rating on Biora Therapeutics Historical earnings data for Biora Therapeutics","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4087220-biora-therapeutics-reports-positive-results-from-its-clinical-trial-of-bt-600","is_publish_highlight":false,"gpt_icon":0},{"id":"2424505775","title":"Biora Therapeutics Full Year 2023 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2424505775","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2424505775?lang=en_us&edition=fundamental","pubTime":"2024-04-02 03:39","pubTimestamp":1712000358,"startTime":"0","endTime":"0","summary":"NasdaqGM:BIOR Earnings and Revenue History April 1st 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 60%. Earnings per share  also surpassed analyst estimates by 2.7%.Looking ahead, revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.The company's shares are down 9.8% from a week ago.Before we wrap up, we've discovered 7 warning signs for Biora Therapeutics (5 make us uncomfortable!","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biora-therapeutics-full-2023-earnings-193918976.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424723047","title":"MMAT, CNTB and HGAS among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2424723047","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424723047?lang=en_us&edition=fundamental","pubTime":"2024-04-02 00:57","pubTimestamp":1711990679,"startTime":"0","endTime":"0","summary":"Gainers: Vast Renewables Ltd  +167%. CXApp  +149%. Sunshine Biopharma  +86%. Xilio Therapeutics  +35%. Doma Holdings  +33%. Meta Materials  +31%. Global Gas Corp  +26%. MoneyHero Ltd  +25%. Connect Biopharma Holdings Ltd  +24%.  Mesoblast Ltd  +21%.  Losers: Eiger BioPharmaceuticals  -70%. Mountain Crest Acquisition Corp IV  -60%. Disc Medicine  -54%. Logistic Properties of the Americas  -42%. AEON Biopharma  -41%. Biora Therapeutics  -31%. Nuvve Holding Corp  -29%. Vivos Therapeutics  -28%. Surrozen  -28%.   More on Mid-day movers & stocks.  Meta Materials total Q4 revenue up 55% y/y Meta Materials announces $1M civil penalty to settle SEC investigation Seeking Alpha’s Quant Rating on Connect Biopharma Historical earnings data for Connect Biopharma Financial information for Connect Biopharma","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4085834-mmat-cntb-and-hgas-among-mid-day-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2424671778","title":"Biora Therapeutics Shares Drop 26% After Pricing of Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2424671778","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2424671778?lang=en_us&edition=fundamental","pubTime":"2024-04-01 21:45","pubTimestamp":1711979100,"startTime":"0","endTime":"0","summary":"Biora Therapeutics shares were down after the company entered into definitive agreements for the purchase and sale of 5.5 million shares at $1.10 a share in a registered direct offering.Shares were down 26% to 81 cents in recent trading. The stock hit its 52-week low of 74 cents earlier in the session, and is down 71% in the past 12 months.In a concurrent private placement, the company will issue unregistered warrants to buy up to 5.5 million shares. The warrants have an exercise price of $1.10 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants, and will expire five years from the date of stockholder approval.The closing of the offering is expected to occur on or about Wednesday.The proceeds to Biora from this offering are expected to be $6 million, before deducting the placement agent's fees and other offering expenses.Biora intends to use the proceeds from this offering to support","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2424196197","title":"Biora Therapeutics announces $6M registered direct offering and concurrent private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2424196197","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424196197?lang=en_us&edition=fundamental","pubTime":"2024-04-01 20:34","pubTimestamp":1711974867,"startTime":"0","endTime":"0","summary":"Biora Therapeutics  said on Monday that it had entered into a securities purchase and sale agreement to purchase ~5.45 million common shares in a registered direct offering priced at the market under Nasdaq rules. Shares of BIOR were down 18.2% in premarket trading.  In a concurrent private placement, BIOR also agreed to issue and sell unregistered warrants to purchase up to ~5.45 million common shares, which will expire five years from the date of stockholder approval. The combined effective offering price for each share of common stock and warrant is $1.10, BIOR added. According to the company, the offering is expected to close on or about April 3, 2024.   More on Biora Therapeutics  Biora Therapeutics announces new capital investment Seeking Alpha’s Quant Rating on Biora Therapeutics Historical earnings data for Biora Therapeutics Financial information for Biora Therapeutics","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4085534-biora-therapeutics-announces-6m-registered-direct-offering-and-concurrent-private-placement","is_publish_highlight":false,"gpt_icon":0},{"id":"2424719504","title":"MSTR, BIOR and ARBK among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2424719504","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424719504?lang=en_us&edition=fundamental","pubTime":"2024-04-01 20:31","pubTimestamp":1711974675,"startTime":"0","endTime":"0","summary":"Losers: Mountain Crest Acquisition Corp IV  -60%. Fractyl Health  -22% reports fourth quarter and full year 2023 financial results. Avalo Therapeutics  -16% after FY earnings release. Biora Therapeutics  -14% announces $6 Million registered direct offering priced at-the-market under Nasdaq rules.  Biodexa Pharmaceuticals Plc  -12%. Cleanspark  -10% bitcoin production jumps 24% M/M in March. Inspira Technologies Oxy B.H.N. Ltd  -9% on $1.65M direct funding. Griid Infrastructure  -8%. Cazoo Group Ltd  -10%. Kidpik Corp  -7%. Argo Blockchain Plc  -6%. Microstrategy  -6%. Aditxt  -5%. Ocean Biomedical  -5%. System1  -5%. Lixte Biotechnology Holdings  -5%.   More on Pre-market losers & stocks.  MicroStrategy Is A $1 Box Of Bitcoin Trading For $1.91 Biora Therapeutics, Inc.  Q4 2023 Earnings Call Transcript MicroStrategy: A Bad Deal For Investors MicroStrategy among most squeezable as crypto short interest climbs Is MicroStrategy, the bitcoin trade, better than Bitcoin?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4085528-mstr-bior-and-arbk-among-pre-market-losers","is_publish_highlight":false,"gpt_icon":0},{"id":"2422921989","title":"BIOR: Negotiations Accelerating","url":"https://stock-news.laohu8.com/highlight/detail?id=2422921989","media":"Zacks Small Cap Research","top":-1,"share":"https://ttm.financial/m/news/2422921989?lang=en_us&edition=fundamental","pubTime":"2024-03-28 00:35","pubTimestamp":1711557300,"startTime":"0","endTime":"0","summary":"Since our previous update in December, Biora Therapeutics, Inc.  has generated compelling data from its BioJet collaborations, initiated its BT-600 Phase I study, completed several cohorts of the study and made beneficial changes to its capital structure. On March 26th, 2024, the company reported full year 2023 results highlighting both the progress that it has made in its clinical program and collaborations. The company has also substantially reduced its debt, dramatically improving the capital structure. Based on the preclinical work that has been completed so far, management is optimistic that they will see a partnership emerge this year.Biora reported full year 2023 results in a press release and Form 8-K filing with the SEC on March 26th. A conference call was held to discuss results with investors following the release. For the financial year ending December 31, 2023 and versus the prior year, insignificant revenues were recognized. Net loss for 2023 totaled  million or  per shar","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ztwUSBYut2tiQSYkdeCOcw--~B/aD01NDI7dz0xNDc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/bf73d1112ae5485baf203171983863bd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ztwUSBYut2tiQSYkdeCOcw--~B/aD01NDI7dz0xNDc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/bf73d1112ae5485baf203171983863bd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bior-negotiations-accelerating-163500167.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422439619","title":"Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2422439619","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2422439619?lang=en_us&edition=fundamental","pubTime":"2024-03-28 00:18","pubTimestamp":1711556282,"startTime":"0","endTime":"0","summary":"Biora Therapeutics, Inc.  Q4 2023 Earnings Call Transcript March 26, 2024 Biora Therapeutics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (. Chuck Pedala : Thank you, Operator. Good afternoon and welcome to the Biora Therapeutics fourth quarter 2023 Corporate Update and Financial Results conference call. Joining me on the call are Adi Mohanty, Chief Executive Officer; Ariella Kelman, Chief Medical Officer; and Eric d'Esparbes, Chief Financial Officer. Before I turn the call over to Mr. Mohanty, I'd like to remind you that today's call will include forward-looking statements within the meeting of the Federal Securities Law, including but not limited to, the types of statements identified as forward-looking in our quarterly report on Form 10-K that we plan to file in the next few days and our subsequent reports filed with the SEC, which are available on our website in the Investors section.Ariella Kelman : Thank you, Adi, and happy to be","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TXEUcnFfjD5bw.rcZ6eQcw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/f26d31c298f15eb40fafc3ad362e9c7b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TXEUcnFfjD5bw.rcZ6eQcw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/f26d31c298f15eb40fafc3ad362e9c7b"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biora-therapeutics-inc-nasdaq-bior-161802538.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422611979","title":"Q4 2023 Biora Therapeutics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2422611979","media":"Thomson Reuters StreetEvents","top":-1,"share":"https://ttm.financial/m/news/2422611979?lang=en_us&edition=fundamental","pubTime":"2024-03-27 18:18","pubTimestamp":1711534735,"startTime":"0","endTime":"0","summary":"Aditya Mohanty; Chief Executive Officer, Director; Biora Therapeutics Inc. Eric d'Esparbes; Chief Financial Officer; Biora Therapeutics Inc. Welcome to the Biora Therapeutics fourth quarter 2023 financial results call.  As a reminder, this conference is being recorded. I will now turn the call over to Chuck Padala, our Managing Director with LifeSci Advisors, Biora's Investor Relations firm.Thank you, Adi, and happy to be here and to speak with you all patients with ulcerative colitis or UC continue to have significant unmet needs and research shows that the inability to achieve high enough lev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2023-biora-therapeutics-inc-101855290.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422678770","title":"BRIEF-Biora Therapeutics Inc And Plaintiffs Agreed To Settle Litigation Related To Co's IPO For An Amount Of $1.0 Million In March 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2422678770","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2422678770?lang=en_us&edition=fundamental","pubTime":"2024-03-27 05:44","pubTimestamp":1711489480,"startTime":"0","endTime":"0","summary":"March 26 (Reuters) - Biora Therapeutics Inc   :   * BIORA THERAPEUTICS INC - IN MARCH 2024, COMPANY AND PLAINTIFFS AGREED TO SETTLE LITIGATION RELATED TO COMPANY'S IPO FOR AN AMOUNT OF $1.0 MILLIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.progenity.com","stockEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.1364},{"period":"3month","weight":-0.1208},{"period":"6month","weight":-0.4635},{"period":"1year","weight":-0.7822},{"period":"ytd","weight":-0.4595}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.014327},{"month":2,"riseRate":0.25,"avgChangeRate":-0.033364},{"month":3,"riseRate":0,"avgChangeRate":-0.131404},{"month":4,"riseRate":0,"avgChangeRate":-0.285334},{"month":5,"riseRate":0.75,"avgChangeRate":0.195047},{"month":6,"riseRate":0.333333,"avgChangeRate":0.023629},{"month":7,"riseRate":0.25,"avgChangeRate":-0.09068},{"month":8,"riseRate":0.5,"avgChangeRate":-0.196023},{"month":9,"riseRate":0.25,"avgChangeRate":0.021914},{"month":10,"riseRate":0.25,"avgChangeRate":0.151023},{"month":11,"riseRate":0,"avgChangeRate":-0.261678},{"month":12,"riseRate":0.5,"avgChangeRate":-0.095454}],"exchange":"NASDAQ","name":"Biora Therapeutics, Inc.","nameEN":"Biora Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biora Therapeutics, Inc.(BIOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biora Therapeutics, Inc.(BIOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biora Therapeutics, Inc.,BIOR,Biora Therapeutics, Inc.股票,Biora Therapeutics, Inc.股票老虎,Biora Therapeutics, Inc.股票老虎国际,Biora Therapeutics, Inc.行情,Biora Therapeutics, Inc.股票行情,Biora Therapeutics, Inc.股价,Biora Therapeutics, Inc.股市,Biora Therapeutics, Inc.股票价格,Biora Therapeutics, Inc.股票交易,Biora Therapeutics, Inc.股票购买,Biora Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biora Therapeutics, Inc.(BIOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biora Therapeutics, Inc.(BIOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction